“…The thrombus produced subsequent to the injury to the vascular endothelium, is platelet-rich and resembles clinically observed thrombi (Matsuno et al, 1991). TXA2, although relatively labile, is synthesized in large quantities by platelets in response to a variety of stimuli (Best et al, 1980;Ambler et al, 1985). Thromboxane receptor antagonists (TRAs) such as vapiprost (Lumley et al, 1989), sulotoroban (Shebuski et al, 1988;Fujita et al, 1988) and Ah-23848 (Brezinski et al, 1988) have been shown to interfer with platelet function through specific competitive inhibition of the platelet membrane receptor that binds either TXA2 or the cyclic endoperoxides intermediate, PGH2.…”